Challenges in Designing HIV Env Immunogens for Developing a Vaccine - Structure-Based Study of Viral Replication - page 375

human immunodeficiency virus type 1 gp140 envelope glycoprotein.
J Virol 76 : 7760-7776.
139. Srivastava IK, Stamatatos L, Kan E, et al . (2003) Purification, charac-
terization, and immunogenicity of a soluble trimeric envelope protein
containing a partial deletion of the V2 loop derived from SF162, an
R5-tropic human immunodeficiency virus type 1 isolate. J Virol 77 :
11244-11259.
140. Srivastava IK, Stamatatos L, Legg H, et al . (2002) Purification and
characterization of oligomeric envelope glycoprotein from a primary r5
subtype B human immunodeficiency virus. J Virol 76 : 2835-2847.
141. Yang X, Farzan M, Wyatt R, Sodroski J. (2000) Characterization of
stable, soluble trimers containing complete ectodomains of human
immunodeficiency virus type 1 envelope glycoproteins. J Virol 74 :
5716-5725.
142. Yang X, Lee J, Mahony EM, et al . (2002) Highly stable trimers formed
by human immunodeficiency virus type 1 envelope glycoproteins fused
with the trimeric motif of T4 bacteriophage fibritin. J Virol 76 :
4634-4642.
143. Yang X, Wyatt R, Sodroski J. (2001) Improved elicitation of neutral-
izing antibodies against primary human immunodeficiency viruses
by soluble stabilized envelope glycoprotein trimers. J Virol 75 :
1165-1171.
144. Barnett SW, Lu S, Srivastava I, et al . (2001) The ability of an
oligomeric human immunodeficiency virus type 1 (HIV-1) envelope
antigen to elicit neutralizing antibodies against primary HIV-1 isolates
is improved following partial deletion of the second hypervariable
region. J Virol 75 : 5526-5540.
145. Srivastava IK, VanDorsten K, Vojtech L, et al . (2003) Changes in the
immunogenic properties of soluble gp140 human immunodeficiency
virus envelope constructs upon partial deletion of the second hyper-
variable region. J Virol 77 : 2310-2320.
146. Cherpelis S, Jin X, Gettie A, et al . (2001) DNA-immunization with a
V2 deleted HIV-1 envelope elicits protective antibodies in macaques.
Immunol Lett 79 : 47-55.
147. Cherpelis S, Shrivastava I, Gettie A, et al . (2001) DNA vaccination
with the human immunodeficiency virus type 1 SF162DeltaV2 enve-
lope elicits immune responses that offer partial protection from
simian/human immunodeficiency virus infection to CD8(+) T-cell-
depleted rhesus macaques. J Virol 75 : 1547-1550.